FORM 7  
  
MONTHLY PROGRESS REPORT

Name of Listed Issuer: *Pivot Pharmaceuticals Inc. (the “Issuer”)*

Trading Symbol: *PVOT*

Number of Outstanding Listed Securities: *88,055,160 common shares*

Date: *April 5, 2018*

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*On March 2, 2018, Pivot completed its previously announced acquisition of Thrudermic, LLC (“Thrudermic”) and Thrudermic’s worldwide rights to the patented TDL Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids. The TDL Transdermal Nanotechnology is intended for the formulation and delivery of dosable bio-cannabis products.*

*On March 2, 2018, Pivot secured a private placement offering of senior secured convertible debentures with a conversion price of $1.74 per common share for aggregate gross proceeds of $5,000,000. Proceeds received will be used to, among other things, fund working capital and general corporate purposes, develop its pipeline of products and acquire intellectual property.*

*During the month, Pivot completed the integration of its California subsidiary, ERS Holdings Ltd. and is currently preparing for a 2018 product launch in California, including the launch of its proprietary line of “Ready-to-Infuse-Cannabis” natural health products.*

*Pivot’s 1% CBD Oral Micelle Solution developed in Germany is ready to market. The development of its two topical creams using Pivot’s patented formulation and delivery systems is now complete. Pivot anticipates that it will have several products available for sale in Canada on the date legalization officially begins.*

*Pivot also secured a listing on the Frankfurt Stock Exchange ("FSE") and commenced trading under the symbol "NPAT". Pivot believes the listing in Germany will give it greater exposure to a European-based investor audience.*

1. Provide a general overview and discussion of the activities of management.

*Please see Item 1.*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*Please see Item 1.*

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*None.*

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*Please see Item 1.*

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*None.*

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*As noted in Item 1, Pivot completed its acquisition of Thrudermic and its worldwide rights to the patented TDL Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids. Consideration, determined through arm’s length discussions, included the issuance of 500,000 common shares of Pivot for intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology and cash payment of US$1 for all of the issued and outstanding units of Thrudermic.*

1. Describe the acquisition of new customers or loss of customers.

*Not applicable.*

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

*Please see Item 1.*

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*Pursuant to the acquisition of Thrudermic as noted in Item 1, the Company entered into employment contracts with Joseph Borovsky as Vice President, Product Formulation and with Leonid Lurya as Executive Director, Product Formulation.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

*Not applicable.*

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*Not applicable.*

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*As noted in Item 1, Pivot secured a private placement offering of senior secured convertible debentures with a conversion price of $1.74 per common share for aggregate gross proceeds of $5,000,000.*

*On March 29, 2018, Pivot repaid its promissory note of US$200,000 entered into on September 11, 2017.*

1. Provide details of any securities issued and options or warrants granted.

*As noted in Item 7, Pivot issued 500,000 common shares pursuant to the acquisition of intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology.*

*During the month, Pivot issued or granted the following:*

* *137,500 common shares to third party service providers,*
* *44,087 common shares pursuant to employment agreements, and*
* *200,000 options to purchase common shares to a third party service provider at an exercise price of $1.67, equal monthly vesting over 12 months and expiry date of March 11, 2023.*

1. Provide details of any loans to or by Related Persons.

*None.*

1. Provide details of any changes in directors, officers or committee members.

*None.*

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

*Pivot, with its cannabis formulation and delivery technologies, continues to look forward to the Canadian market’s legalization of cannabis-based products.*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 5, 2018

Moira Ong   
Name of Director or Senior Officer

*“Moira Ong”*   
Signature

Chief Financial Officer   
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer  Pivot Pharmaceuticals Inc. | For Month End  March 2018 | Date of Report  YY/MM/D  2018/04/05 |
| Issuer Address  1275 West 6th Avenue, Suite 300 | | |
| City/Province/Postal Code  Vancouver, BC V6H 1A5 | Issuer Fax No.  ( ) | Issuer Telephone No.  ( ) |
| Contact Name  Patrick Frankham | Contact Position  CEO | Contact Telephone No.  514-943-1899 |
| Contact Email Address  info@pivotpharma.com | Web Site Address  www.pivotpharma.com | |